Research Topics
| Kristel Van LaethemSummaryAffiliation: Katholieke Universiteit Leuven Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypesKristel Van Laethem
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
J Virol Methods 132:181-6. 2006..The population sequences of the three other samples lacked a part of the sequence because of heterogeneous signal, probably due to the presence of quasi-species with insertions/deletions of a different length...- No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugsKristel Van Laethem
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
J Clin Virol 39:43-7. 2007..Resistance testing has been implemented into clinical guidelines as it has shown some beneficial effect on subsequent therapy response... - Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct waysKristel Van Laethem
Rega Institute for Medical Research, Katholieke Universiteit Leuven, and AIDS Reference Laboratory, University Hospitals Leuven, Leuven, Belgium
Infect Genet Evol 7:600-3. 2007..In vitro culturing in the presence of tenofovir resulted in further enhancement of phenotypic resistance levels towards tenofovir and nucleoside reverse transcriptase inhibitors due to the development of K65R... - A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope geneKristel Van Laethem
Rega Institute for Medical Research and University Hospitals Leuven, Microbiology and Immunology, Clinical and Epidemiological Virology, AIDS Reference Laboratory, Minderbroedersstraat 10, Leuven 3000, Belgium
J Virol Methods 123:25-34. 2005..This study demonstrates that the assay is able to genotype genetically diverse HIV-1 strains with a good sensitivity... 
A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypesKristel Van Laethem
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
J Virol Methods 153:176-81. 2008..The relevance of these polymorphisms in the absence of the signature mutations remains unclear...- Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypesKris Covens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
J Clin Virol 44:325-8. 2009..However, most studies include only subtype B strains, while it is known that especially the env region is very divergent among subtypes... 
Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic useJan Balzarini
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Antimicrob Agents Chemother 54:1425-35. 2010..It proved stable at high temperature and low pH. Therefore, PRM-S may qualify as a potential anti-HIV drug candidate for further (pre)clinical studies, including its microbicidal use...- Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelopeBart Hoorelbeke
Rega Institute for Medical Research, Minderbroedersstraat 10, Leuven B 3000, Belgium
Antimicrob Agents Chemother 54:3287-301. 2010.... - Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscapeKristof Theys
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
BMC Bioinformatics 11:409. 2010..By simulation of evolution over this landscape, the individualized genetic barrier to NFV resistance may be estimated for an isolate... - The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtideKris Covens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
Antiviral Res 86:253-60. 2010.... - Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIVJan Balzarini
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
J Biol Chem 280:41005-14. 2005..It forces HIV to escape drug pressure by deleting the indispensable glycans on its GP120, thereby obligatorily exposing previously hidden immunogenic epitopes on its envelope... - Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic interventionJoeri Auwerx
Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Virology 382:10-9. 2008..The gp120 V1/V2 loop glycans of HIV-1 should therefore be considered as a hot spot and novel target for specific therapeutic drug intervention... - Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypesInge Derdelinckx
Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000, Leuven, Belgium
FEMS Immunol Med Microbiol 39:119-24. 2003..45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes... - Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006Jurgen Vercauteren
Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
AIDS Res Hum Retroviruses 24:355-62. 2008..e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium... - Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratoryBart Maes
Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
J Virol Methods 119:45-9. 2004..3% of the cases where primer A failed. Most of these positive results were subtype B (74%). As a result of sequencing problems 65 out of 351 (18.5%) samples had to be processed with "in-house" procedures... - Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological responseKoen Deforche
Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
Antivir Ther 13:399-407. 2008..A method has been developed to estimate a fitness landscape experienced by HIV-1 under treatment selective pressure as a function of the genotypic sequence thereby also estimating the genetic barrier to resistance... - Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalisJan Balzarini
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
Mol Pharmacol 67:1556-65. 2005..The mutant viruses containing the deleted glycosylation sites were markedly more infectious in CEM T-cell cultures than wild-type virus... - Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virusJan Balzarini
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
J Virol 81:362-73. 2007.... - Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugsKris Covens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
J Clin Microbiol 47:2232-42. 2009.... - Bayesian network analyses of resistance pathways against efavirenz and nevirapineKoen Deforche
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
AIDS 22:2107-15. 2008..To clarify the role of novel mutations selected by treatment with efavirenz or nevirapine, and investigate the influence of HIV-1 subtype on nonnucleoside reverse transcriptase inhibitor (nNRTI) resistance pathways... - Profile of resistance of human immunodeficiency virus to mannose-specific plant lectinsJan Balzarini
Rega Institute for Medical Research, Gent, Belgium
J Virol 78:10617-27. 2004..The plant lectins represent a well-defined class of anti-HIV (microbicidal) drugs with a novel HIV drug resistance profile different from those of other existing anti-HIV drugs... - Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopesJan Balzarini
Rega Institute for Medical Research, KU Leuven, Belgium
J Virol 80:8411-21. 2006.... - HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype GAna Carolina Palma
Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
J Antimicrob Chemother 67:1075-9. 2012..The purpose of this study was the qualitative and quantitative assessment of the in vitro effect of HIV-1 protease (PR) mutation 82M on replication capacity and susceptibility to the eight clinically available PR inhibitors (PIs)... - Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg databaseJean Ruelle
Universite Catholique de Louvain, AIDS Reference Laboratory, Avenue Hippocrate 54 5492, 1200 Bruxelles, Belgium
BMC Infect Dis 8:21. 2008..Guidelines established for the treatment of HIV-1 infection and genotype interpretation do not apply for HIV-2. Data about antiretroviral (ARV) drug efficacy and resistance mutations is scarce... - Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001Joke Snoeck
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
J Acquir Immune Defic Syndr 35:279-85. 2004.... - Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidinesJan Balzarini
Rega Institute for Medical Research, K U Leuven, B 3000 Leuven, Belgium
J Antimicrob Chemother 59:80-6. 2007..To discover new potent and selective anti-human immunodeficiency virus (HIV) acyclic nucleoside phosphonate (ANP) drugs with in vivo antiretroviral activity... - Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activityBart Hoorelbeke
Rega Institute for Medical Research, K, U, Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Retrovirology 8:10. 2011..Both lectins are tetrameric proteins sharing 64% sequence similarity... - Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibilityKurt Vermeire
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
J Virol 83:9577-83. 2009..In addition, the acquired ability of a CADA-resistant virus to infect cells with low CD4 expression was associated with an increased susceptibility of the virus to neutralizing antibodies from sera of several HIV-1-infected patients... - env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitorsValery Fikkert
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
Antimicrob Agents Chemother 46:3954-62. 2002..In addition, we obtained a proof of principle that env CVT can become a helpful diagnostic tool in assessments of the phenotypic resistance of clinical HIV isolates to HIV entry inhibitors... - Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsKristof Theys
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Retrovirology 9:81. 2012.... - Interpreting resistance data for HIV-1 therapy management--know the limitationsKristel Van Laethem
Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
AIDS Rev 8:37-43. 2006..All these analysis are of value, but still display some weak points. However, due to the fast evolving know-how in the field, a prospective trial in which different systems are compared head-to-head will be difficult to design... - A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patientsKristel Van Laethem
Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Belgium
Antivir Ther 7:123-9. 2002..However, it should be subject to regular updates as is needed in this fast developing field... - Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3' untranslated region of flaviviruses with no known vectorNathalie Charlier
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
J Gen Virol 83:1875-85. 2002..The availability of this latter sequence motif allows us to designate a virus as either an NKV or a vector-borne flavivirus... - Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanionsJoeri Auwerx
Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Antiviral Res 83:61-70. 2009..The excess value of CBAs and polyanions to prevent HIV-1 capture and transmission by DC-SIGN and L-SIGN-expressing cells to susceptible T-lymphocytes could be of interest for the development of new drug leads targeting HIV entry/fusion... - Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck
Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
Antimicrob Agents Chemother 50:694-701. 2006..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype... - Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12Dana Huskens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Virology 360:294-304. 2007..This is, to our knowledge, the first report showing that a resistant virus generated in vitro against a neutralizing mAb and containing a mutation in gp120, has increased sensitivity to another class of HIV entry inhibitors... - Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999Joke Snoeck
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000, Belgium
Virus Res 85:95-107. 2002..The other non-B subtypes and the recombinants are mainly introduced by immigrants or by Belgian citizens traveling abroad... - Molecular testing of multiple HIV-1 transmissions in a criminal casePhilippe Lemey
Rega Institute, KULeuven, B 3000 Leuven, Belgium
AIDS 19:1649-58. 2005..To test the a priori hypothesis of HIV-1 transmission from one suspect to six recipients in a criminal case... - Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approachDimitrios Paraskevis
Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
Retrovirology 6:49. 2009..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced... - The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypesDavid A van de Vijver
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04-614, 3584 CX Utrecht, The Netherlands
J Acquir Immune Defic Syndr 41:352-60. 2006..Because of differences in minor protease substitutions, protease inhibitor resistance could be enhanced in particular subtypes once the relevant major substitutions are selected... - Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profileSonia de Castro
, Juan de la Cierva 3, Madrid, Spain
Antiviral Res 71:15-23. 2006..The deaminated TSAO compound must fit differently in the HIV-1 RT enzyme than its prototype TSAO-m(3)T... - Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chainPhilippe Lemey
Department of Zoology, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom
J Virol 79:11981-9. 2005.... - Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical managementAnnemarie M J Wensing
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
J Infect Dis 192:958-66. 2005..These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated... - Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patientsLaurence Vergne
UMR145/UR36, IRD, University of Montpellier, Montpellier, France
FEMS Immunol Med Microbiol 46:53-62. 2006.... - Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolatesLuis M F Gonzalez
Departamento de Genetica, Universidade Federal do Rio de Janeiro, CCS Bloco A, sala A2 120, Cidade Universitária Ilha do Fundão, Rio de Janeiro RJ 21949 970, Brazil
J Antimicrob Chemother 61:1201-4. 2008..We have previously shown a strong statistical interdependency of residues 71, 89 and 90 in subtype G, but the impact of substitutions on protease inhibitor (PI) resistance is unknown... - Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluationJean Marie Zimmer
Retrovirology Laboratory, Centre de Recherche Publique Santé, Luxembourg, Luxembourg
J Acquir Immune Defic Syndr 48:255-62. 2008..We also showed that when confronted with too many mutations to evaluate in vitro, MD simulations are helpful to draft hypotheses on how polymorphisms can interact with resistance mutations to stabilize their potential fitness cost... - HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithmsJaideep Ravela
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94301, USA
J Acquir Immune Defic Syndr 33:8-14. 2003..Determining the clinical significance of these mutation patterns responsible for interalgorithm discordances will improve interalgorithm concordance and the accuracy of genotypic resistance interpretation... - Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring systemRainer Ziermann
Bayer HealthCare LLC, Diagnostics Division, 800 Dwight Way, Berkeley, CA 94710, USA
J Clin Virol 31:S7-15. 2004..5, and VGI GuideLines Rules 4.0) were statistically significantly correlated with virologic therapy response as measured by viral load testing... - Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment responseInge Derdelinckx
J Acquir Immune Defic Syndr 37:1664-6. 2004 - Fatal brain necrosis in primary HIV infectionWouter Meersseman
Department of Internal Medicine, Rega Institute, Katholieke Universiteit and University Hospitals Leuven, B-3000 Leuven, Belgium
Lancet 366:866. 2005